Remove Embolism Remove Strokes Remove Thrombosis
article thumbnail

Abelacimab Stops Bleeding, But Stroke Impact Uncertain

CardiacWire

Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.

Strokes 59
article thumbnail

Management of complications associated with percutaneous left atrial appendage closure with or without ablation: experience from 512 cases over a 4-year period

Frontiers in Cardiovascular Medicine

These included three cases of intraoperative thrombosis, three instances of pericardial effusion or tamponade, one case of device-related thrombosis, one peri-device leak, one systemic embolism, one bleeding episode, and one additional device-related complication.

article thumbnail

Epidemiology, Pathophysiology, and Imaging of Atherosclerotic Intracranial Disease

Stroke Journal

Stroke, Volume 55, Issue 2 , Page 311-323, February 1, 2024. Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide. In addition to stroke, ICAD increases the risk of dementia and cognitive decline, magnifying ICAD societal burden.

article thumbnail

Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding Risk

DAIC

These results suggest that abelacimab may be safe across the spectrum of bleeding risk and may make it possible to anticoagulate some of the most vulnerable populations who otherwise would not be treated and therefore left unprotected from the risk of stroke. Data from these trials are expected in the second half of 2026.

article thumbnail

Abstract 4145271: Systemic Lupus Erythematosus-Induced Libman-Sacks Endocarditis Complicated by Multiple Embolic Episodes and Atypical Secondary Valve Involvement

Circulation

A 42-year-old female with SLE, lupus cerebritis with related seizure disorder, and mesenteric venous thrombosis on warfarin initially presented for syncope. Acute stroke workup was negative, and syncope was attributed to possible brief seizure. Circulation, Volume 150, Issue Suppl_1 , Page A4145271-A4145271, November 12, 2024.

article thumbnail

MP-483492-002 COMPARATIVE EFFECTIVENESS OF DIFFERENT MANAGEMENT STRATEGIES FOR LEFT ATRIAL APPENDAGE THROMBUS IN PATIENTS ON OPTIMAL NOAC THERAPY

HeartRhythm

Left atrial appendage (LAA) thrombus is the primary cause of stroke and systemic embolism in atrial fibrillation (AF). Novel oral anticoagulants (NOACs) effectively reduce the prevalence of LAA thrombosis and stroke risk.

article thumbnail

Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases

Stroke: Vascular and Interventional Neurology

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4